Bull case strengthens as summer cross currents -2-
UPDATE: 'Smart beta' indexed ETFs sure attract a lot of dumb money
UPDATE: Charting the U.S. markets' technical -2-
Charting the U.S. markets' technical cross -2-
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.
As the sector has continued to best the broader market, a look both at the dynamics that would drive further outperformance by the sector and at funds that investors can use to tap those themes.
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...
Jerry Slusiewicz depends on his own analysis and risk-management philosophy to keep client portfolios in order.
The five biotech ETFs have very different portfolios with markedly different performance.